RT Journal Article
SR Electronic
T1 Dermatomyositis: Muscle Pathology According to Antibody Subtypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.03.21258156
DO 10.1101/2021.06.03.21258156
A1 Jantima Tanboon
A1 Michio Inoue
A1 Yoshihiko Saito
A1 Shinichiro Hayashi
A1 Satoru Noguchi
A1 Naoko Okiyama
A1 Manabu Fujimoto
A1 Ichizo Nishino
YR 2021
UL http://medrxiv.org/content/early/2021/06/05/2021.06.03.21258156.abstract
AB Importance Current pathological criteria of dermatomyositis (DM) do not recognize different features among DM subtypes classified by dermatomyositis-specific antibodies (DMSAs).Objective To determine whether myopathological features differ among DM subtypes classified by DMSAs and whether the pathological features can be characterized by serologically defined DM subtype.Design Retrospective review of muscle pathology slides of 256 patients diagnosed with DM from January 2009 to December 2020.Setting Single center study in a tertiary laboratory for muscle diseases.Participants A total of 256 patients whose DM diagnosis was pathologically confirmed based on the sarcoplasmic expression of myxovirus resistant protein A (MxA) were included. Of these, 249 patients were positive for one of the 5 DMSAs (seropositive patients, anti-TIF1-γ=87, anti-Mi-2=40, anti-MDA5=29, anti-NXP-2=83, and anti-SAE=10), and 7 were negative for all 5 DMSAs (seronegative patients).Exposure Histochemical, enzyme histochemical, immunohistochemical staining, and ultrastructural study.Main outcomes and measures Histological features stratified according to four pathology domains: muscle fiber, inflammatory, vascular, and connective tissue domains, and histological features of interest by histochemistry, enzyme histochemistry, and immunohistochemical study commonly used in the diagnosis of inflammatory myopathy.Results DMSAs significantly associated with characteristic histochemical and immunohistochemical features were as follows: anti-TIF1-γ with vacuolated/punched out fibers (64.7%, P<.001) and perifascicular enhancement in HLA-ABC (75.9%, P<.001); anti-Mi-2 with prominent muscle fiber damage (score 4.8±2.1, P<.001), inflammatory cell infiltration (score 8.0±3.0, P=.002), perifascicular atrophy (67.5%, P=.02), perifascicular necrosis (52.5%, P<.001), increased perimysium alkaline phosphatase activity (70.0%, P<.001), central necrotic peripheral regenerating fibers (45.0%, P<.001), and sarcolemmal deposition of the membrane attack complex (67.5%, P<.001); anti-MDA5 with scattered/diffuse staining pattern of MxA (65.5%, P<.001) with less muscle pathology and inflammatory features; and anti-NXP2 with microinfarction (26.5%, P<.001); and anti-SAE and seronegative DM with HLA-DR expression (50.0%, P=.02 and 57.1%, P=.02 respectively).Conclusion and relevance We described an extensive study on serological-pathological correlation of DM primarily using MxA expression as an inclusion criterion. DMSAs was associated with distinctive myopathological features in our studied cohort, suggesting that different pathobiological mechanisms may underscore each subtype.Question Are myopathological features different among dermatomyositis (DM) subtypes classified by DM-specific autoantibodies (DMSAs)? If so what are the characteristic features of each subtype?Findings This study enrolled 256 (249 DMSA-positive and 7 seronegative) patients whose DM diagnosis was made pathologically by confirming the expression of myxovirus resistant protein A in the sarcoplasm of muscle fibers in muscle biopsy samples. The DM subtypes classified by the positive DMSAs were associated with distinctively characteristic pathological features.Meaning Different pathological features suggest different pathological mechanisms may well underly each DM subtype classified by DMSA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by Intramural Research Grant 29-4 for Neurologic and Psychiatric Disorders of the National Center of Neurology and Psychiatry.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review boards of the NCNP. All clinical information and materials derived from diagnostic testing and was permitted for research use with written informed consent from the patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny anonymized data relevant to the study not published within the article will be shared at the request of any qualified investigator.